Nupep-L Capsule SR is a sustained-release formulation combining Levosulpiride 75 mg and Esomeprazole 40 mg, designed to provide effective management of gastrointestinal disorders characterized by dyspepsia, gastroesophageal reflux disease (GERD), and functional dysmotility. Levosulpiride, a selective dopamine D2 receptor antagonist, enhances gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as bloating, nausea, and abdominal discomfort. Esomeprazole, a proton pump inhibitor, suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, promoting mucosal healing and reducing acid-related irritation. The sustained-release mechanism ensures a prolonged therapeutic effect, optimizing symptom control and improving patient compliance. Nupep-L Capsule SR is indicated for patients with combined acid-peptic disorders and motility dysfunction, providing a dual-action approach to symptom relief and mucosal protection. It should be administered as prescribed by a healthcare professional, with consideration of patient-specific factors including comorbidities and concomitant medications. Common adverse effects may include headache, dizziness, and mild gastrointestinal disturbances. Caution is advised in patients with renal or hepatic impairment. Regular monitoring and adherence to prescribed dosage are essential to maximize therapeutic benefits and minimize potential risks.